EYLEA® 8mg MOA

Mechanism of action

EYLEA® 8mg provides 4x the molar dose of aflibercept compared with EYLEA® 2mg, resulting in an effective concentration for longer in the eye.,*

What is a Higher Molar Dose?

Theoretically, a higher Molar dose is able to suppress disease activity longer than Eylea® 2mg thereby resulting in sustained disease control, in the eye.*

Based on mathematical modelling and the clinical relevance is unknown

*Based on mathematical modelling and the clinical relevance is unknown.

    DME, diabetic macular edema. Fc, fragment crystallisable. IgG, immunoglobulin G. nAMD, neovascular (wet) age-related macular degeneration. PK, pharmacokinetic. PIGF, placental growth factor. VEGF, vascular endothelial growth factor. VEGFR, vascular endothelial growth factor receptor.

PP-EYL_8mg-IL-0023-1

    • 1
      EYLEA® 8mg SmPC as approved by the Israeli MoH.
    • 2
      Veritti D,
      et al. Pharmaceutics
      2023;15:1416.